ArticleArthritis care & research2011
Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.
Article in Arthritis care & research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network.RMD open · 2023Article
- Review
- Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.BMC infectious diseases · 2022Article
- Duration of prednisone treatment before development ofJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Giant cell arteritis treatment patterns and rates of serious infections.Clinical and experimental rheumatology · 2022Article
- [S2k guidelines: management of large-vessel vasculitis].Zeitschrift fur Rheumatologie · 2020Review
- Morbidity and Mortality of Large-Vessel Vasculitides.Current rheumatology reports · 2020Review
- Boundaries of a systemic disease: a protean presentation of giant cell arteritis.BMJ case reports · 2020Article
- Updates in the Diagnosis and Management of Giant Cell Arteritis.Current neurology and neuroscience reports · 2019Review
- Therapy and Management ofJournal of fungi (Basel, Switzerland) · 2018Review
- Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?Current rheumatology reports · 2017Review
- Infection Risk and Safety of Corticosteroid Use.Rheumatic diseases clinics of North America · 2016Review
- Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.Digestive diseases and sciences · 2015Article
- Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.The New England journal of medicine · 2014Review
- [Large vessel vasculitis].Zeitschrift fur Rheumatologie · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo describe the clinical presentation, laboratory findings, and outcome of patients with Pneumocystis jiroveci pneumonia (PCP) and biopsy-proven giant cell arteritis (GCA) seen at a tertiary referral center.
methodsUsing International Classification of Diseases, Ninth Revision codes, all patients with GCA and PCP between January 1, 1976 and December 31, 2008 were identified. Medical records were reviewed. PCP was defined by the identification of Pneumocystis jiroveci organisms in the clinical setting of pneumonia.
resultsWe identified 7 patients with GCA (5 women and 2 men) who developed PCP (the mean ± SD age at diagnosis was 71.6 ± 6.1 years). The median time from GCA diagnosis to PCP diagnosis was 3 months (range 1-18 months). All patients were taking prednisone (the median dosage 50 mg/day [range 30-80]) when diagnosed as having PCP. No patients were receiving PCP prophylaxis. PCP was diagnosed by positive smear on bronchoalveolar lavage fluid in 6 patients (86%) and by positive sputum polymerase chain reaction in 1 patient. All the patients were hospitalized (median duration 17 days [range 12-39 days]). Four patients (57%) were admitted to the intensive care unit. Three patients (43%) required mechanical ventilation. Two patients (29%) died; both were on mechanical ventilation.
conclusionAlthough PCP is rare among patients with GCA, this preventable infection is associated with significant morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.